Back to top

Surging Earnings Estimates Signal Good News for Adaptimmune Therapeutics (ADAP)
September 21, 2017

Read MoreHide Full Article

Adaptimmune Therapeutics plc (ADAP - Free Report) is a clinical-stage biopharmaceutical company that could be an interesting play for investors. That is because, not only does the stock have decent short-term momentum, but it is seeing solid activity on the earnings estimate revision front as well.

These positive earnings estimate revisions suggest that analysts are becoming more optimistic on ADAP’s earnings for the coming quarter and year. In fact, consensus estimates have moved sharply higher for both of these time frames over the past four weeks, suggesting that Adaptimmune Therapeutics could be a solid choice for investors.

Current Quarter Estimates for ADAP

In the past 30 days, one estimate have gone higher for Adaptimmune Therapeutics while none have gone lower in the same time period. The trend has been pretty favorable too, with estimates narrowing from a loss of 29 cents a share 30 days ago, to a loss of 27 cents today, a move of 6.9%.

Current Year Estimates for ADAP

Meanwhile, Adaptimmune Therapeutics’ current year figures are also looking quite promising, with two estimates moving higher in the past month, compared to none lower. The consensus estimate trend has also seen a boost for this time frame, narrowing from a loss $1.07 per share 30 days ago to a loss of 95 cents per share today, a move of 11.2%.

Adaptimmune Therapeutics PLC Price and Consensus

Bottom Line

The stock has also started to move higher lately, adding 64.3% over the past four weeks, suggesting that investors are starting to take note of this impressive story. So investors may definitely want to consider this Zacks Rank #3 (Hold) stock to profit in the near future. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Will You Make a Fortune on the Shift to Electric Cars?

Here's another stock idea to consider. Much like petroleum 150 years ago, lithium power may soon shake the world, creating millionaires and reshaping geo-politics. Soon electric vehicles (EVs) may be cheaper than gas guzzlers. Some are already reaching 265 miles on a single charge.

With battery prices plummeting and charging stations set to multiply, one company stands out as the #1 stock to buy according to Zacks research.
It's not the one you think.

See This Ticker Free >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


Adaptimmune Therapeutics PLC (ADAP) - free report >>


More from Zacks Tale of the Tape

You May Like